219
Participants
Start Date
April 15, 2020
Primary Completion Date
March 3, 2022
Study Completion Date
March 10, 2022
Empagliflozin
Empagliflozin
Placebo
Placebo
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Peking University Third Hospital, Beijing
Beijing Pinggu Hospital, Beijing
Shengjing Hospital of China Medical University, Shenyang
The Second Hospital of Jilin University, Changchun
Tongren hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Centre Hospital of Putuo District, Shanghai, Shanghai
Shanghai Fifth People's Hospital affiliated to Fudan University, Shanghai
The Second Affiliated Hospital of Nanjing Medical University, Hangzhou
Suzhou Municipal Hospital, Suzhou
The First Affiliated Hospital of Soochow University, Suzhou
Anhui Provincial Hospital, Hefei
The affiliated hospital of medicalcollege qingdao university, Qingdao
Tianjin Medical University Chu Hisen-I Memorial Hospital, Tianjin
The Affiliated Hospital of Hangzhou Normal University, Hangzhou
Jiangxi Provincial People's Hospital, Nanchang
The First Affiliated Hospital of Nanchang University, Nanchang
The Second Affiliated Hospital to Nanchang University, Nanchang
The First Hospital, Chongqing Medical University, Chongqing
Chongqing Three Gorges Central Hospital, Chongqing
The third xiangya hospital of Central South University, Changsha
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Third Affiliated Hospital of Guangzhou Medical University, Guangzhou
Lead Sponsor
Boehringer Ingelheim
INDUSTRY